The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of regorafenib in progressive, recurrent/metastatic adenoid cystic carcinoma.
 
Alan Loh Ho
Honoraria - Novartis
Consulting or Advisory Role - Eisai; Novartis
Research Funding - AstraZeneca; Bayer; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly
Travel, Accommodations, Expenses - Janssen Oncology
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Bayer; Eisai
 
Shrujal S. Baxi
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca
 
Sofia Haque
No Relationships to Disclose
 
Ai Ni
No Relationships to Disclose
 
Cristina R. Antonescu
No Relationships to Disclose
 
Nora Katabi
No Relationships to Disclose
 
Luc G. Morris
No Relationships to Disclose
 
Timothy An-thy Chan
No Relationships to Disclose
 
David G. Pfister
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - AstraZeneca; Bayer; Boehringer Ingelheim; Exelixis; Genentech; GlaxoSmithKline; Lilly; MedImmune; Merck; Novartis